Growing evidence suggests that SCD1 activation plays a cell-protective role in various metabolic tissues as well as kidney cells [32,33,34], and thus an SCD1 activator is expected to become a novel therapy for preventing disease progression associated with diabetes. Here, SCD is linked to diabetes mellitus.